New combo targets 'Zombie Cells' to fight liver scarring
NCT ID NCT05506488
Summary
This study tested whether a combination of two drugs, dasatinib and quercetin, could reduce liver scarring (fibrosis) in people with fatty liver disease. Thirty adults with confirmed liver scarring participated in this early-stage trial. The goal was to see if clearing certain aged 'senescent' cells in the liver could improve the condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amsterdam UMC location AMC
Amsterdam, Netherlands
Conditions
Explore the condition pages connected to this study.